Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Impact of formulation on the iontophoretic delivery of the FOLFIRINOX regimen for the treatment of pancreatic cancer

Impact of formulation on the iontophoretic delivery of the FOLFIRINOX regimen for the treatment... Purpose Effective treatment of patients with locally advanced pancreatic cancer is a significant unmet clinical need. One major hurdle that exists is inadequate drug delivery due to the desmoplastic stroma and poor vascularization that is char- acteristic of pancreatic cancer. The local iontophoretic delivery of chemotherapies provides a novel way of improving treatment. With the growing practice of highly toxic combination therapies in the treatment of pancreatic cancer, the use of iontophoresis for local delivery can potentiate the anti-cancer effects of these therapies while sparing unwanted toxicity. The objective of this study was to investigate the impact of formulation on the electro-transport of the FOLFIRINOX regimen for the development of a new treatment for pancreatic cancer. Methods Three formulations of the FOLFIRINOX regimen (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) were generated at a fixed pH of 6.0 and were referred to as formulation A (single drug solution with all four drugs combined), formulation B (two drug solutions with two drugs per solution), and formulation C (four individual drug solutions). Anodic iontophoresis of the three different formulations was evaluated in orthotopic patient-derived xenografts of pancreatic cancer. Results Iontophoretic transport of the FOLFIRINOX drugs was characterized according to organ exposure after a http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cancer Chemotherapy and Pharmacology Springer Journals

Impact of formulation on the iontophoretic delivery of the FOLFIRINOX regimen for the treatment of pancreatic cancer

Download PDF
8 pages

Loading next page...
 
/lp/springer_journal/impact-of-formulation-on-the-iontophoretic-delivery-of-the-folfirinox-u5x4RyKvQ8
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer-Verlag GmbH Germany, part of Springer Nature
Subject
Medicine & Public Health; Oncology; Pharmacology/Toxicology; Cancer Research
ISSN
0344-5704
eISSN
1432-0843
DOI
10.1007/s00280-018-3570-3
Publisher site
See Article on Publisher Site

Abstract

Purpose Effective treatment of patients with locally advanced pancreatic cancer is a significant unmet clinical need. One major hurdle that exists is inadequate drug delivery due to the desmoplastic stroma and poor vascularization that is char- acteristic of pancreatic cancer. The local iontophoretic delivery of chemotherapies provides a novel way of improving treatment. With the growing practice of highly toxic combination therapies in the treatment of pancreatic cancer, the use of iontophoresis for local delivery can potentiate the anti-cancer effects of these therapies while sparing unwanted toxicity. The objective of this study was to investigate the impact of formulation on the electro-transport of the FOLFIRINOX regimen for the development of a new treatment for pancreatic cancer. Methods Three formulations of the FOLFIRINOX regimen (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) were generated at a fixed pH of 6.0 and were referred to as formulation A (single drug solution with all four drugs combined), formulation B (two drug solutions with two drugs per solution), and formulation C (four individual drug solutions). Anodic iontophoresis of the three different formulations was evaluated in orthotopic patient-derived xenografts of pancreatic cancer. Results Iontophoretic transport of the FOLFIRINOX drugs was characterized according to organ exposure after a

Journal

Cancer Chemotherapy and Pharmacology – Springer Journals

Published: Mar 30, 2018

References

  • Pancreatic cancer: from state-of-the-art treatments to promising novel therapies
    Garrido-Laguna, I; Hidalgo, M
  • Surgery for recurrent pancreatic ductal adenocarcinoma
    Kleef, J; Reiser, C; Hinz, U; Bachmann, J; Debus, J; Jaeger, D; Friess, H; Büchler, MW
  • Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer
    Olive, KP; Jacobetz, MA; Davidson, CJ; Gopinathan, A; McIntyre, D; Honess, D; Madhu, B; Goldgraben, MA; Caldwell, ME; Allard, D; Frese, KK; Denicola, G; Feig, C; Combs, C; Winter, SP; Ireland-Zecchini, H; Reichelt, S; Howat, WJ; Chang, A; Dhara, M; Wang, L; Rückert, F; Grützmann, R; Pilarsky, C; Izeradjene, K; Hingorani, SR; Huang, P; Davies, SE; Plunkett, W; Egorin, M; Hruban, RH; Whitebread, N; McGovern, K; Adams, J; Iacobuzio-Donahue, C; Griffiths, J; Tuveson, DA
  • Stromal biology and therapy in pancreatic cancer: a changing paradigm
    Neesse, A; Algül, H; Tuveson, DA; Gress, TM
  • Local iontophoretic administration of cytotoxic therapies to solid tumors
    Byrne, JD; Jajja, MR; O’Neill, AT; Bickford, LR; Keeler, AW; Hyder, N; Wagner, K; Deal, A; Little, RE; Moffitt, RA; Stack, C; Nelson, M; Brooks, CR; Lee, W; Luft, JC; Napier, ME; Darr, D; Anders, CK; Stack, R; Tepper, JE; Wang, AZ; Zamboni, WC; Yeh, JJ; DeSimone, JM
  • Iontophoretic device delivery for the localized treatment of pancreatic ductal adenocarcinoma
    Byrne, JD; Jajja, MR; Schorzman, AN; Keeler, AW; Luft, JC; Zamboni, WC; DeSimone, JM; Yeh, JJ
  • Iontophoretic drug delivery
    Kalia, YN; Naik, A; Garrison, J; Guy, RH
  • Targeted local simultaneous iontophoresis of chemotherapies for topical therapy of head and neck cancers
    Gratieri, T; Kalia, YN
  • FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer
    Conroy, T; Desseigne, F; Ychou, M; Bouché, O; Guimbaud, R; Bécouarn, Y; Adenis, A; Raoul, JL; Gourgou-Bourgade, S; Fouchardière, C; Bennouna, J; Bachet, JB; Khemissa-Akouz, F; Péré-Vergé, D; Delbaldo, C; Assenat, E; Chauffert, B; Michel, P; Montoto-Grillot, C; Ducreux, M
  • Virtual microdissection identifies distinct tumor- and stroma specific subtypes of pancreatic ductal adenocarcinoma
    Moffitt, RA; Marayati, R; Flate, EL; Volmar, KE; Loeza, SG; Hoadley, KA; Rashid, NU; Williams, LA; Eaton, SC; Chung, AH; Smyla, JK; Anderson, JM; Kim, HJ; Bentrem, DJ; Talamonti, MS; Iacobuzio-Donahue, CA; Hollingsworth, MA; Yeh, JJ
  • Effects of the HDAC inhibitor CG2 in combination with irinotecan, 5-fluorouracil, or oxaliplatin on HCT116 colon cancer cells and xenografts
    Na, YS; Kim, SM; Jung, KA; Yang, SJ; Hong, YS; Ryu, MH; Ro, S; Cho, DH; Kim, JC; Jin, DH; Lee, JS; Kim, TW
  • Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts
    Azrak, RG; Cao, S; Slocum, HK; Tóth, K; Durrani, FA; Yin, MB; Pendyala, L; Zhang, W; McLeod, HL; Rustum, YM
  • Synergistic antitumoral activity of combined UFT, folinic acid and oxaliplatin against human colorectal HT29 cell xenografts in athymic nude mice
    Louvet, C; Coudray, AM; Tournigand, C; Prévost, S; Raymond, E; Gramont, A; Chazard, M; Gespach, C
  • Structure and inhibition of microbiome β-glucuronidases essential to the alleviation of cancer drug toxicity
    Wallace, BD; Roberts, AB; Pollet, RM; Ingle, JD; Biernat, KA; Pellock, SJ; Venkatesh, MK; Guthrie, L; O’Neal, SK; Robinson, SJ; Dollinger, M; Figueroa, E; McShane, SR; Cohen, RD; Jin, J; Frye, SV; Zamboni, WC; Pepe-Ranney, C; Mani, S; Kelly, L; Redinbo, MR
  • LC–MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients
    Büchel, B; Rhyn, P; Schürch, S; Bühr, C; Amstutz, U; Largiadèr, CR
  • Evaluation of drug loading, pharmacokinetic behavior, and toxicity of a cisplatin-containing hydrogel nanoparticle
    Kai, MP; Keeler, AW; Perry, JL; Reuter, KG; Luft, JC; O’Neal, SK; Zamboni, WC; DeSimone, JM
  • Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial
    Hammel, P; Huguet, F; Laethem, JL; Goldstein, D; Glimelius, B; Artru, P; Borbath, I; Bouché, O; Shannon, J; André, T; Mineur, L; Chibaudel, B; Bonnetain, F; Louvet, C
  • Approach to patients with pancreatic cancer without detectable metastases
    Heestan, GM; Murphy, JD; Lowy, AM
  • A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma
    Indolfi, L; Ligorio, M; Ting, DT; Xega, K; Tzafriri, AR; Bersani, F; Aceto, N; Thapar, V; Fuchs, BC; Deshpande, V; Baker, AB; Ferrone, CR; Haber, DA; Langer, R; Clark, JW; Edelman, ER
  • A 3D-printed local drug delivery patch for pancreatic cancer growth suppression
    Yi, HG; Choi, YJ; Kang, KS; Hong, JM; Pati, RG; Shim, IK; Lee, CM; Kim, SC; Cho, DW
  • Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors
    Wu, H; Infante, JR; Keedy, VL; Jones, SF; Chan, E; Bendell, JC; Lee, W; Kirschbrown, WP; Zamboni, BA; Ikeda, S; Kodaira, H; Rothenberg, ML; Burris, HA; Zamboni, WC
  • The role of electroosmotic flow in transdermal iontophoresis
    Pikal, MJ
  • Modulation of pancreatic cancer chemoresistance by inhibition of TAK1
    Melisi, D; Xia, Q; Paradiso, G; Ling, J; Moccia, T; Carbone, C; Budillon, A; Abbruzzese, JL; Chiao, PJ
  • Predicting the chemosensitivity of pancreatic cancer cells by quantifying the expression levels of genes associated with the metabolism of gemcitabine and 5-fluorouracil
    Kurata, N; Fujita, H; Ohuchida, K; Mizumoto, K; Mahawithitwong, P; Sakai, H; Onimaru, M; Manabe, T; Ohtsuka, T; Tanaka, M
  • Genetically defined subsets of human pancreatic cancer demonstrate unique in vitro chemosensitivity
    Cui, Y; Brosnan, JA; Blackford, A; Sur, S; Hruban, RH; Kinzler, KW; Vogelstein, B; Maitra, A; Diaz, LA; Iacobuzio-Donahue, CA; Eshleman, JR